ArticleBlood neoplasia2026

Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models.

Janneke A Eken et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.